Monitor the HSR clearance and any updates on development timeline for civorebrutinib. The recent executive departure (May 21) could indicate management transition; watch for further changes or clarity on leadership. The deal adds pipeline value but increases near-term cash burn.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $42.96entry
- T+1 · 6mo ago +5.21%α +5.94% · $45.20
- T+5 · 5mo ago +13.06%α +16.02% · $48.57
- T+20 · 5mo ago +31.15%α +32.71% · $56.34
- T+60 · 3mo ago +56.24%α +55.12% · $67.12
Price Chart
How similar events traded
Executive Summary
Travere Therapeutics entered into a license and collaboration agreement with EverestMedicines for exclusive rights to develop and commercialize civorebrutinib (BTK inhibitor) outside China and Southeast Asia. Travere will pay $112.5M upfront with up to ~$1.03B in milestones and tiered royalties. The deal expands Travere's pipeline in immune-mediated kidney diseases but carries development and cash burn risks. A recent executive departure (8-K filed May 21) adds uncertainty around management continuity.
Key Financial Metrics
Key Facts
- Exclusive license for civorebrutinib (EVER001), a BTK inhibitor, for all therapeutic uses outside China and parts of Southeast Asia
- Upfront payment of $112.5 million to Everest
- Potential milestones up to approximately $1.03 billion across up to five indications
- Tiered royalties from high single-digit to double-digit percentages on net sales
- Travere responsible for development and commercialization in the Territory; cost-sharing on global trials
- Agreement subject to HSR waiting period and other customary conditions
- Prior 8-K (May 21, 2026) disclosed an executive departure and equity plan amendment
Financial Impact
Upfront payment of $112.5 million, plus up to $1.03 billion in contingent milestones and tiered royalties
Risk Factors
- Cash burn from $112.5M upfront and ongoing development costs
- Clinical and regulatory risks for civorebrutinib (still in development)
- Potential management disruption from recent executive departure
- Competition in BTK inhibitor space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252474 |
| Document: 0001193125-26-252474-index-headers.html | 0001193125-26-252474 |
| Document: 0001193125-26-252474-index.html | 0001193125-26-252474 |
| Document: 0001193125-26-252474.txt | 0001193125-26-252474 |
Track record
21 reports on TVTX
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +49.98% at T+60 after the Feb 28, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Viewing Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers